secwatch.observer — SEC 8-K summary
======================================

Issuer:     Co-Diagnostics, Inc. (CODX)
CIK:        0001692415
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001493152-24-030746
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Co-Diagnostics Q2 revenue jumps to $2.7M, net loss narrows to $7.6M, submits 510(k) for PCR platform
--------------------------------------------------------------------------------

- Revenue of $2.7M vs $0.2M in prior year, driven by milestone achievements on grants.
- Net loss of $7.6M ($0.25/share) improved from $8.9M ($0.31/share) YoY; adjusted EBITDA loss of $5.9M.
- Operating loss of $7.7M compared to $12.0M in 2023; cash and securities of $44.9M as of June 30.
- Submitted first 510(k) for Co-Dx PCR Pro platform with OTC COVID-19 test to FDA.
- Opened new manufacturing facility in South Salt Lake for Co-Primers and PCR platform components.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1692415/000149315224030746/0001493152-24-030746-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1692415/000149315224030746/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-030746

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer